Conclusions: We demonstrated that tumor-reactive CD8 + T cell subsets which persist after TIL therapy are mostly polyfunctional, display a stable partially differentiated phenotype and express high levels of PD-1. These partially differentiated PD-1 + polyfunctional TILs have a high capacity for persistence and may be susceptible to PD-L1/PD-L2-mediated inhibition.
Statement of Translational Relevance
Infusion of autologous tumor-infiltrating lymphocytes can induce dramatic and durable clinical responses in patients with widely metastatic cancers. Persistence of tumor-reactive T cells in the circulation is strongly associated with tumor regression, thus the identification of T cell subsets with greater persistence may pave the way to more effective cellular immunotherapies.
In this study, we identified a CD8 + T cell subset with high persistence. This tumor-reactive CD8 + T cell subset generates polyfunctional immune responses and exhibits a stable but partially differentiated phenotype. Sustained upregulation of PD-1 in polyfunctional tumor-reactive CD8 + T cells make them susceptible to PD-L1/PD-L2 mediated inhibition, and interfering with this signaling pathway may prolong clinical responses. Our results suggest that these partially differentiated, PD-1 + , polyfunctional TILs may hold the key to continuous immune surveillance.
Introduction
Ideal cancer treatment should induce durable tumor regression to give a meaningful life extension.
In melanoma, work performed in the context of previous clinical trials based on transfer of autologous tumor-infiltrating lymphocytes (TILs) have identified a number of factors influencing the likelihood of tumor regression (1) (2) (3) (4) (5) . However, despite the high degree of efficacy, over 50% of patients with significant tumor regression achieve only a temporary, partial remission (1) . Sustained tumor responses may be dependent on the long-term fate of the infused tumor-specific T cells.
However, the attributes of these persisting T cell populations are largely unknown. Current TIL treatment regimens are based on a single infusion of expanded T cells derived from an autologous tumor metastasis. These T cells are not selected for any specific class or type of antigen, so this treatment takes advantage of a multitarget T cell attack directed to multiple and mostly unknown antigenic specificities, including mutant neo-antigens (6) . Current methods reveal the existence of neo-antigen specific T cells in TILs from most patients with melanoma; however, whole tumor-cell recognition assays indicate that the frequency of naturally occurring tumor-specific T cells may largely exceed those observed for the neo-antigens evaluated (7) . Libraries of known shared antigens have been constructed and validated (8) , but greatly underestimate the frequency of tumorspecific cells (9) . Here, we evaluated the immunological dynamics (immunodynamics) of the total repertoire of tumor-reactive CD8 + T cells identified with whole-tumor cell recognition assays, regardless of the type or class of melanoma antigens recognized. This comprehensive analysis allowed the identification of several common features of CD8 + T cell responses that persisted for up to 1 year after infusion.
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Methods

Patients and clinical trial
All protocols were approved by the Scientific Ethics Committee of the Capital Region of Denmark.
Written informed consent was obtained from patients before any procedure, according to the Declaration of Helsinki. Patients were treated with TIL immunotherapy in the clinical trial NCT00937625. This clinical trial consisted of two consecutive sub-studies: a pilot study (n=6), with a low dose of IL-2 administered after T-cell infusion (2 MIU/day subcutaneously for 14 days) (10); an amended study (n=25), with an intensified regimen of IL-2 (decrescendo i.v. regimen or intermediate dose) (5) . Blood samples were collected at serial time points after infusion of TILs: at discharge (about 1-2 weeks after infusion) and at approximately 1 month, 2 months, 4 months, 6 months, 9 months (this sample was analyzed only in functional evaluation, see below) and 12 months, unless the patient was excluded from the protocol at a previous time point. Peripheral blood mononuclear cells (PBMCs) were isolated with standard methods, and cryopreserved at -140 °C until use. We included sixteen selected patients where previous tumor recognition assays had identified sufficient numbers of tumor reactive T cells in the peripheral blood after infusion (described in (5)). Phenotypic assessment of T cells with defined antigen specificity and clonotypic analysis of tumor-reactive TILs were conducted each on three selected patients. All other analyses included at least thirteen patients. We were unable to include the three remaining patients (total cohort of 16) in all analyses due to insufficient sample material.
Polyfunctionality and Phenotype of tumor-reactive CD8 + T cells
Evaluation of T cell responses was performed as previously described (5, 11 Group 1 contained one of the markers from group 4, group 2 two of the markers from group 4 and group 3 three of the markers from group 4. In brief, a score from 0 to 4 was assigned to TP (triple positive) cells, with 0 representing the less differentiated cells to 4 the most differentiated. This is shown in Supplementary Figure S6A , where intra-sample analyses (i.e. the frequency of TP cells contained in each group, for each sample) are demonstrated. Furthermore, one single combined "Differentiation Score" was given to each sample (each patient, at each time point), by multiplying the arcsine transformed value of the frequency of cell subpopulations contained in the groups described above, with a pre-defined score for each group which was 0 for early effector cells (group 0) and 4 for late effector cells (group 4) as described above (intermediate values 1-3 were given to cells with 1, 2 or 3 phenotypic markers). The differentiation score of each sample is demonstrated in Figure 3B . Supplementary Figure S1 shows a graphical representation of the scoring system and the unique T cell subpopulations analyzed are reported in Table S1 . In addition, boolean combination gates of the four phenotype markers resulting in 16 individual gates were analyzed and processed as 
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Out of sixteen TIL-treated patients selected on the basis of the availability of samples and measurable antitumor responses in the peripheral blood, 10 had response evaluation criteria in solid tumors (RECIST) version 1.0 confirmed responses and three additional patients had minor tumor regressions including unconfirmed partial responses. Two patients had stable disease and only one patient, M27, was classified as pure progressor after infusion of TILs. The predominance of responding patients in this cohort was largely expected, as we have previously shown that the detection of tumor-reactive CD8 + T cells in the peripheral blood lymphocyte (PBL) pool after TIL infusion is strongly associated with tumor regression (5).
Polyfunctionality of tumor-reactive CD8 + T cells
It is believed that T cells expressing multiple functions may mediate superior immune responses (17) and polyfunctionality is known to correlate with antigen-sensitivity and TCR binding affinity (18) . We have previously shown that over 95% of CD8 + T cells expressing at least one out of seven antitumor functions express either TNF, IFN or CD107a (11) . Thus, we limited our analyses to these three functional markers. A retrospective analysis of our previously published dataset on TIL recognition of autologous melanoma cells (11) indicates that the fraction of CD8 + T cells expressing Figure S2D) . This suggests that CD107a mobilization was mainly associated with cytokine production, while cytokine production could occur independently of CD107a upregulation.
Thus, we initially focused on CD8 + T cells expressing cytokines, and to increase the sensitivity of the analysis, primary on those expressing simultaneously TNF and IFN (double positive or DP cells). Notably, among DP cells, the percentage of cells expressing CD107a increased over time in all (n=13; median r 2 0.63) but one patient ( Figure 1A ). CD107a is a surrogate marker of lytic granule release and, therefore, the capacity of T cells to directly destroy tumor cells (19) . In this context, it is interesting that the only patient where the CD107a + fraction decreased was the one patient who, despite detection of tumor-reactive CD8 + T cells in post-infusion blood samples, had a significantly progressive disease at first evaluation after treatment, and was quickly excluded from the study (patient M27, Table 1 ). In light of this finding, we analyzed whether the frequency of Therefore, it cannot be excluded that the observed phenomenon might be explained, at least in part, by IL-2 withdrawal, as previously reported in vitro (26) . Similarly, CD57 expression exhibited a progressive trend from around 2-5% in the infusion product to almost 37% 12 months after treatment ( Figure 2D ). In contrast, around 75% of TP cells in the infusion product expressed CD45RO, which was mirrored 1 week later in the PBMCs before dropping to about 50% at over 1 month post infusion ( Figure 2E ). Parallel increase in CD57 + and decrease in CD45RO + were detected in non-tumor reactive CD8 + T cells (Supplementary Figure S4D , S4E, S5B and S5C).
Comparison of phenotype markers in TP and non-tumor reactive CD8 + T cells revealed difference only for CD57 in the infusion products (Supplementary Figure S5B) , and major differences in the peripheral pools for PD-1 ( Figure 3A ) and CD57 (Supplemenraty Figure S5B) 
TCR diversity appeared to rise post-treatment as indicated by an increase in Shannon entropy. Thus, whereas many tumor-reactive T cell clones can persist for at least 6 months after infusion, other T cell populations arise in the periphery over time from de novo recruitment or from expansion of rare clones present in the infusion product at frequencies below our limits of detection. The presence of tumor-reactive clonotypes in the blood that were not present in the infusion product might suggest epitope spreading.
Phenotype of CD8 + T cells with defined tumor-antigen specificity
In order to gain insights on whether the observed phenotype changes occur in the repertoires of infused CD8 + T cells targeting a defined antigen, and whether similar phenotype changes could be detected in resting cells (phenotype of TP cells might be influenced by T cell activation upon recognition of naturally presented tumor-antigens), we carried out similar phenotype analyses focusing on CD8 + T cells recognizing known tumor-associated antigens as detected by p-MHC multimer staining. Samples from three patients with high-frequencies of CD8 + T cells with defined tumor-antigen specificity were selected for these analyses (Supplementary Figure S8A) . We observed a similar trend as seen in TP CD8 + T cells, with patterns of strong LAG-3 downregulation (data not shown), increase of PD-1 ( Figure 5A ), decrease of CD45RO ( Figure 5B ) and increase of CD57 ( Figure 5C ). Similar to TP CD8 + T cells, the increase of PD-1 appeared larger in tumorantigen specific CD8 + T cells (Supplementary Figure S8B) . CD27 did not increase as much as observed in whole pool of tumor-reactive CD8 + T cells ( Figure 5D ). However current data does not allow to establish whether the more pronounced changes observed in tumor-reactivity experiments were due to the activated state of TP CD8 + T cells or whether this discrepancy was simply due to the small sample size of p-MHC experiments. Combinatorial analysis of surface markers of these populations was similar to that seen on TP CD8 + T cells (compare pie charts in Supplementary Figure S7 with Supplementary Figure S8C ).
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Discussion
Optimization of cellular immunotherapies requires a detailed understanding of the dynamic processes leading to establishment of long-term immunological memory. We conducted a detailed, sequential, multidimensional analysis of bulk tumor-reactive T cell populations derived from melanoma patients treated with TILs, dissecting dynamic functional and phenotypic changes of antitumor CD8 + T cells. Polyfunctionality is a highly desirable feature of potent CD8 + T cells, well known in infections (17), but only recently described in cancer immunity (11, 27) . This feature is known to correlate with antigen-sensitivity and TCR affinity for cognate antigen (18, 28) . We previously in patients with melanoma (31) .
Importantly, the pattern of polyfunctionality and phenotypic markers that is established within the first month after TIL therapy is then maintained for at least a year. In this context, we proposed a differentiation scoring system based on combinatorial expression of CD27, CD45RO, CD57 and PD-1. This system is imperfect due to the known instability of some markers such as CD27, and the absence of other potentially important markers such as CD62L and CCR7. Nevertheless, this system proved useful for visualizing the global phenotypic dynamics up to 1 year following infusion of TILs ( Figure 3B ).
We also investigated whether individual T cells within the infusion product could persist in patient blood after treatment by examining the clonotypic architecture of the tumor-specific response in the infusion product and patient blood 6 months after treatment. These results confirmed that some 
